Dietary ExposureNCT06102122
Acceptability and Tolerance Study of Adult Tube Feed with Food with Food Derived Ingredients.
A study testing Compleat in people with Dietary Exposure, run by Société des Produits Nestlé (SPN) at 1 site in United Kingdom.
Trial summary
Product acceptability data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) submission for Ireland for product registration. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Dietary Exposure
- What is being tested?
- Compleat
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 22 Aug 2023to 22 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Require a tube feed (taking >75% of energy needs from their feeding tube) as part of their dietary management for disease related malnutrition
- Adults and children requiring an adult enteral formula as assessed by the dietitian.
- Patients well-established and stable on a standard formula or currently on Isosource® Junior Mix.
- Willingly given, written, informed consent from patient or consultee. For those who lack capacity to provide formal consent for themselves, this may be provided by a personal or consultee in accordance with the Mental Capacity Act.
- Willingly given, written assent (if appropriate) on behalf of patients under 18.
Who cannot join
- Inability to comply with the study protocol, in the opinion of the investigator
- Known food allergies to any ingredients (see ingredients list)
- Patients with significant renal or hepatic impairment - Change in current medication or use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file).
- Participation in another interventional study within 2 weeks of this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: To Evaluate the Acceptability (including Gastrointestinal Tolerance and Compliance) of an Adult Tube-feed Formula with Ingredients Derived from Food.
Product acceptability data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) submission for Ireland for product registration.
Read the detailed description
To evaluate the acceptability (including gastrointestinal tolerance and compliance) of an adult tube-feed formula with ingredients derived from food for the dietary management of participants who require a tube feed. .
The acceptability data from 15 participants will be collected in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service
Executive (HSE) for Ireland. Participants will be provided with one month supply of tube feed and will be asked to complete a daily diary and short questionnaire to record information allowing assessment of the following:
- Gastrointestinal tolerance
- Compliance with prescribed feed volumes
- Conditions
- Dietary Exposure
- Being tested
- Compleat
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CompleatDietary supplement
Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
| Study group | Role | What they receive |
|---|---|---|
| Patients well established on tube feeds will act as their own control | Other | Patients will switch from current to new tube feed. Receives: Dietary Supplement: Compleat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Daily record via participant diary
Daily Gastrointestinal diary as questionnaire, increase, decrease or no change
Measured: 7 days
Formula intake diary
mL per day
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2023
- Study start22 Aug 2023
- Primary completion15 Sep 2023
- Study completion22 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dietary ExposureStudies of the same condition, open and under way.
- More trials run by Société des Produits Nestlé (SPN)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Tanita Flood, Principal investigator, Royal Hospital for Neuro-disabilityMartha Van der Linde, Principal investigator, Community Paediatric Dietitian Worcestershire, Hastings UKMinal Patel, Principal investigator, Barts and London Hospital Trust London UKAdrian Gilson, Principal investigator, Newham General Hospital London UK
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06102122
- Sponsor's protocol ID
- Compleat 001
- Status last verified
- Apr 2024
- First submitted
- 22 Aug 2023
- Last updated
- 23 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Will upload the data as it becomes available
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Evaluate the Acceptability (including Gastrointestinal Tolerance and Compliance) of an Adult Tube-feed Formula with Ingredients Derived from Food.
- ClinicalTrials.gov ID
- NCT06102122
- Acronym / sponsor ID
- Compleat 001
- Conditions
- Dietary Exposure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Société des Produits Nestlé (SPN)Industry (pharma, biotech, devices)
- Study start
- 22 Aug 2023 (actual)
- Primary completion
- 15 Sep 2023 (actual)
- Study completion
- 22 Dec 2023 (actual)
- First posted
- 26 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Product acceptability data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) submission for Ireland for product registration.
Detailed description
To evaluate the acceptability (including gastrointestinal tolerance and compliance) of an adult tube-feed formula with ingredients derived from food for the dietary management of participants who require a tube feed. .
The acceptability data from 15 participants will be collected in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service
Executive (HSE) for Ireland. Participants will be provided with one month supply of tube feed and will be asked to complete a daily diary and short questionnaire to record information allowing assessment of the following:
- Gastrointestinal tolerance
- Compliance with prescribed feed volumes
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients well established on tube feeds will act as their own control | Other | Dietary Supplement: CompleatPatients will switch from current to new tube feed. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Require a tube feed (taking >75% of energy needs from their feeding tube) as part of their dietary management for disease related malnutrition
- Adults and children requiring an adult enteral formula as assessed by the dietitian.
- Patients well-established and stable on a standard formula or currently on Isosource® Junior Mix.
- Willingly given, written, informed consent from patient or consultee. For those who lack capacity to provide formal consent for themselves, this may be provided by a personal or consultee in accordance with the Mental Capacity Act.
- Willingly given, written assent (if appropriate) on behalf of patients under 18.
Key exclusion criteria (4 listed)
- Inability to comply with the study protocol, in the opinion of the investigator
- Known food allergies to any ingredients (see ingredients list)
- Patients with significant renal or hepatic impairment - Change in current medication or use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file).
- Participation in another interventional study within 2 weeks of this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CompleatPatients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch | Dietary supplement | Patients well established on tube feeds will act as their own control |
Primary outcome
Daily record via participant diary
Time frame: 7 days
Daily Gastrointestinal diary as questionnaire, increase, decrease or no change
Formula intake diary
Time frame: 28 days
mL per day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2024.
- Individual participant dataSharing planned: No. Will upload the data as it becomes available
Related trials for Dietary Exposure
Recruiting
Ambient Air and Noise Effect on Cardiovascular Health Risk and Lifestyle Intervention to Attenuate It (METSGREEN)
Cardiovascular Diseases (CVD), Metabolic Syndrome
RecruitingPhase 3
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
Kidney Stone, Nephrolithiasis
Recruiting
Tasting Plant Forward Meals
Dietary Exposure
Recruiting
Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters
Environmental Exposure, PFAS Exposure
Not yet recruitingObservational study
Non-Invasive Assessment of Early Health Determinants in Children and Adolescents
Cardiometabolic Health Indicators, Child Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tanita Flood principal investigator
Royal Hospital for Neuro-disability
Martha Van der Linde principal investigator
Community Paediatric Dietitian Worcestershire, Hastings UK
Minal Patel principal investigator
Barts and London Hospital Trust London UK
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Compleat in people with Dietary Exposure, run by Société des Produits Nestlé (SPN) at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Daily record via participant diary (time frame: 7 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2024.